Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Clinical trial NCT01062152 · COMPLETED

Trial details

NCT number: NCT01062152
Sponsor: Telik
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Myelodysplastic Syndrome

Start date: 2009-11-01
Primary completion: 2012-11-01
Enrollment: 19

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.